Anthem Biosciences Board of Directors

Get the latest insights into the leadership at Anthem Biosciences. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Ajay Bhardwaj Chairman & M.D & CEO
Mr. Ganesh Sambasivam Whole Time Director
Mr. K Ravindra Chandrappa Whole Time Director
Mr. Satish Chander Subbanna Non Exe. & Nominee Director
Mr. Ramesh Ramadurai Ind. Non-Executive Director
Mr. Ravikant Uppal Ind. Non-Executive Director
Mr. Subramanian Madhavan Ind. Non-Executive Director
Ms. Shubha Kulkarni Ind. Non-Executive Director

Anthem Biosciences Share price

ANTHEM

844

20.35 (2.47%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:57 IST
BUYSELL
Today's High

858.00

Today's Low

828.15

52 Week Low

701.90

52 Week High

864.90

The current prices are delayed, login to your account for live prices

Anthem Biosciences FAQs

The board at Anthem Biosciences consists of experienced professionals, including Mr. Ajay Bhardwaj , Mr. Ganesh Sambasivam , and others, overseeing the company’s strategic and corporate governance.

Directors at Anthem Biosciences are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Ajay Bhardwaj is the current chairman at Anthem Biosciences.

Executive directors at Anthem Biosciences are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Anthem Biosciences adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Anthem Biosciences, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.